Cargando…

JAK2-tree: a simple CBC-based decision rule to guide appropriate JAK2 V617F mutation testing

AIMS: The JAK2 V617F mutation is highly recurrent in many of the myeloproliferative neoplasms, a molecular variant that can be easily detected using sensitive and minimally invasive techniques. Given the ease of JAK2 V617F testing, this test may be improperly requested for the purposes of patient ‘s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahe, Etienne, Pedersen, Kasper Mønsted, Çolak, Yunus, Bojesen, Stig Egil, Lynch, Tarah, Sinclair, Gary, Khan, Faisal, Shabani-Rad, Meer-Taher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6388913/ https://www.ncbi.nlm.nih.gov/pubmed/30514740 http://dx.doi.org/10.1136/jclinpath-2018-205527

Ejemplares similares

Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020)

Loss-of-function polymorphism in IL6R reduces risk of JAK2V617F somatic mutation and myeloproliferative neoplasm: A Mendelian randomization study
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020)

Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020)

Two-fold risk of pneumonia and respiratory mortality in individuals with myeloproliferative neoplasm: A population-based cohort study
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020)

JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles
por: Hekimoğlu, Hilal, et al.
Publicado: (2022)

The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective
por: Staerk, Judith, et al.
Publicado: (2012)

JAK2 and Beyond: JAK2V617 Mutational Study of Myeloproliferative Disorders and Haematological Malignancies
por: Syeed, Nidda
Publicado: (2019)

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

The JAK2 V617F mutation in isolated neutropenia
por: Langabeer, Stephen E.
Publicado: (2018)

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms
por: Allain-Maillet, Sophie, et al.
Publicado: (2020)

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
por: Lee, A-Jin, et al.
Publicado: (2021)

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
por: Gäbler, Karoline, et al.
Publicado: (2013)

JAK out of the box: myeloproliferative neoplasms--associated JAK2 V617F mutations contribute to aortic aneurysms
por: Elf, Shannon E.
Publicado: (2021)

JAK2 V617F and the evolving paradigm of polycythemia vera
por: Means, Robert T.
Publicado: (2010)

Hemochromatosis, Erythrocytosis and the JAK2 p.V617F Mutation
por: Langabeer, Stephen E.
Publicado: (2017)

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
por: Guy, Alexandre, et al.
Publicado: (2020)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
por: Ferdowsi, Shirin, et al.
Publicado: (2016)

MicroRNA-101 expression is associated with JAK2V617F activity and regulates JAK2/STAT5 signaling
por: Pagano, Francesca, et al.
Publicado: (2018)

PB2178: EVALUATION OF JAK2 EXON 12 MUTATIONS IN PATIENTS WITH JAK2 (V617F)-NEGATIVE POLYCYTHEMIA VERA
por: Khosravi, Sahar, et al.
Publicado: (2023)

Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation
por: Sugimori, C, et al.
Publicado: (2012)

International external quality assurance of JAK2 V617F quantification
por: Asp, Julia, et al.
Publicado: (2018)

The JAK2 V617F mutation in retinal vein or artery occlusion
por: Langabeer, Stephen E.
Publicado: (2019)

Chorea Associated with JAK2(V617F) ‐Positive Essential Thrombocythemia
por: Calculli, Alessandra, et al.
Publicado: (2022)

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)
por: Zhao, Shixiang, et al.
Publicado: (2016)

JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells
por: Wolf, Alexandra, et al.
Publicado: (2013)

PB2192: JAK2 V617F ALLELE BURDEN AND THROMBOTIC EVENTS IN PATIENTS WITH JAK2 V617F POSITIVE POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA AT HIGH RISK OF THROMBOSIS
por: Hwang, Yun Hui, et al.
Publicado: (2023)

JAK2 V617F: A Single Mutation in the Myeloproliferative Group of Disorders
por: McLornan, Donal, et al.
Publicado: (2006)

Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F
por: Zaleskas, Virginia M., et al.
Publicado: (2006)

Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms
por: Stein, Brady L., et al.
Publicado: (2011)

Development of a highly sensitive method for detection of JAK2V617F
por: Zhao, Anna H, et al.
Publicado: (2011)

Crystal structures of the Jak2 pseudokinase domain and the pathogenic mutant V617F
por: Bandaranayake, Rajintha M., et al.
Publicado: (2012)

Jak2V617F myeloproliferative neoplasm stem cells and interferon-alpha
por: Lane, Steven W., et al.
Publicado: (2013)

Identification of AIM2 as a downstream target of JAK2V617F
por: Liew, Ei Leen, et al.
Publicado: (2016)

Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms
por: ZHANG, SHU-PENG, et al.
Publicado: (2015)

Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome
por: Braun, Theodore P., et al.
Publicado: (2014)

Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation
por: Caocci, Giovanni, et al.
Publicado: (2017)

Exploring redox vulnerabilities in JAK2(V617F)-positive cellular models
por: Lima, Keli, et al.
Publicado: (2021)

Clonal Hematopoiesis and JAK2V617F Mutations in Patients With Cardiovascular Disease
por: Yokokawa, Tetsuro, et al.
Publicado: (2021)

Crucial role of hematopoietic JAK2 V617F in the development of aortic aneurysms
por: Yokokawa, Tetsuro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pf8nhik16aifvmi2qi8s01ut22